ARYx Therapeutics, Inc.
6300 Dumbarton Circle
Fremont,
CA 94555
United States - Map
Phone: 510-585-2200
Fax: 510-585-2202
Web Site: http://www.aryx.com
| ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of product candidates designed to eliminate known safety issues associated with commercial drugs using its RetroMetabolic Drug Design technology. The company’s products in Phase II clinical trials include ATI-7505 for the treatment of various gastrointestinal disorders, ATI-5923 for the treatment of patients at risk for the formation of dangerous blood clots, and ATI-2042 for the treatment of patients with atrial fibrillation. Its preclinical development stage product comprises ATI-9242 for the treatment of schizophrenia and other psychiatric disorders. In addition, the company’s late stage discovery programs consist of ATI-20,000 and ATI-24,000, which focuses on metabolic and gastrointestinal disorders. ARYx Therapeutics, Inc. was incorporated in 1997 and is based in Fremont, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Paul Goddard Ph.D., 58
Chairman and Chief Exec. Officer |
$
689.00K |
$
115.00K | Dr. Peter G. Milner M.D., 52
Co-Founder, Pres of R&D |
$
390.00K | N/A | Dr. Pascal Druzgala Ph.D., 53
Co-Founder, Chief Scientific Officer and Sr. VP |
$
312.00K | N/A | Mr. John W. Varian , 49
Chief Operating Officer and Chief Financial Officer |
$
372.00K | N/A | Mr. David Nagler , 55
VP of Corp. Affairs and Sec. |
$
294.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
2.12% Nasdaq 
Profile
